AGC Biologics Archives | Page 2 of 3

Home / Posts tagged AGC Biologics (Page 2)

AGC Biologics Names Regina Choi-Rivera New General Manager of Boulder, Colorado Mammalian Production Facility

Boulder, Colo., Jan. 18 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder. In this role, she assumes executive oversight and leadership and will manage strategic development and facility operations. “We’re incredibly [...]

AGC Biologics Receives Transatlantic Award for Investments in Milan Biopharmaceutical Industry

Milan, Dec. 20 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center [...]

I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project

Seattle, Dec. 13 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of [...]

4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab

Seattle, Dec. 1 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure. Under the terms of [...]

AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer

Seattle, Nov. 1 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Jean-Baptiste Agnus has been appointed as the company’s Chief Business Officer (CBO). In this position, he is responsible for strategic leadership over all aspects of the company’s global business development and sales and marketing teams. “Jean-Baptiste [...]

AGC Biologics Expands pDNA and mRNA Manufacturing Capacity at Heidelberg Facility

Heidelberg, Germany, Sept. 13 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects. With this expansion, AGC Biologics is boosting its current 100L and 1,000L manufacturing capacities for a variety [...]

AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site

COPENHAGEN, Aug. 20 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announces the groundbreaking of its new facility at its Copenhagen, Denmark site. This multipurpose facility will allow AGC Biologics to increase its capacity and space to accommodate new and existing clients’ needs. The new facility will include [...]

AGC Biologics Appoints Tony Fraij as the New General Manager/Site Head of the Longmont, Colorado Site

LONGMONT, Aug. 9 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new leadership appointment to oversee strategic development and operational excellence in large-scale C&GT production at its Longmont site in Colorado. Effective August 9, 2021, Tony Fraij will join the Longmont team as General Manager/Site [...]

AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings

Seattle, Aug. 5 (Korea Bizwire) — AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the finalization of the purchase of a state-of-the-art commercial manufacturing facility in Longmont, Colorado, USA. The facility, previously owned by Novartis Gene Therapies, will provide AGC Biologics with significant additional capacity and space to continue to [...]

AGC Biologics Appoints Kevin Ingham as the New General Manager/Site Head of Their Seattle, Washington Site

Seattle, Aug. 2 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new appointment to oversee the strategic development and operational excellence in clinical and commercial biologics production at its Seattle, Washington site. Effective August 2, 2021, Kevin Ingham will join the Seattle team as the [...]